Global R&D Pipeline
My Favorite
Hot Targets:
CD33
Back
Total number of drugs
149
Phase II and later clinical stages
0.7%
Involving companies
140
Main therapeutic areas
Neoplasms
Data Table
Data Chart
Select Row
Fixed Column
Download Table
Molecule Info
R&D and Market Info
ADC Info
| Drug | Drug Name En | Drug Type | Treatment Field | Mechanism of Action | Originator | Developer | Indication | Highest Development Stage | Highest Development Stage (China) | Approved Countries/Regions | Approved Time | Approved Time (China) | Special Review | ADC Type | ADC Linker | ADC Payload | ADC DAR | Drug Name | Antibody Type | ADC Linking Site | Operation |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| COVA4231 | COVA4231 | Bispecific T-cell Engager (BiTE) | Neoplasms Hemic and Lymphatic Diseases | CD3 stimulants CD33 inhibitors | Covagen AG | Covagen AG | Preclinical | - | - | - | - | - | - | - | - | - | COVA4231 | - | - | detail > | |
| CD33-GADLEN(Shattuck Labs) | CD33-GADLEN(Shattuck Labs) | Antibody fusion proteins | Neoplasms | CD33 modulators | Shattuck Labs, Inc. | Shattuck Labs, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | CD33-GADLEN(Shattuck Labs) | - | - | detail > | |
| CD33 Exon 2 Skipping Oligonucleotide(Entrada) | CD33 Exon 2 Skipping Oligonucleotide(Entrada) | ASO | Nervous System Diseases | CD33 modulators | Entrada Therapeutics, Inc. | Entrada Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | CD33 Exon 2 Skipping Oligonucleotide(Entrada) | - | - | detail > | |
| 27T32 | 27T32 | CAR-T | Neoplasms Hemic and Lymphatic Diseases | CD33 modulators CLL-1 modulators | 2seventy Bio, Inc. | 2seventy Bio, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | 27T32 | - | - | detail > | |
| INB-633 | INB-633 | T cell engagers (TCE) | Neoplasms Hemic and Lymphatic Diseases | CD33 stimulants | IN8bio, Inc. | IN8bio, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | INB-633 | - | - | detail > | |
| GLK-33 | GLK-33 | Antibody drug conjugate (ADC) | Neoplasms Hemic and Lymphatic Diseases | CD33 inhibitors Cytokines inhibitors Tubulin inhibitors Immunostimulants | Glykos Finland Oy | Glykos Finland Oy | Preclinical | - | - | - | - | - | Lintuzumab | - | MMAU | 8 | GLK-33 | IgG1 - kappa | - | detail > | |
| KD-105 | KD-105 | Monoclonal antibody | Neoplasms | CD33 inhibitors | Nanjing KAEDI Biotech, Inc. | Nanjing KAEDI Biotherapeutics Co, Ltd. | Preclinical | Preclinical | - | - | - | - | - | - | - | - | KD-105 | - | - | detail > | |
| CD33-targeting CAR program (Hrain Biotechnology) | CD33-targeting CAR program (Hrain Biotechnology) | Cell therapy | - | CD33 modulators | Hrain Biotechnology Co., Ltd. | Hrain Biotechnology Co., Ltd. | Discovery | Discovery | - | - | - | - | - | - | - | - | CD33-targeting CAR program (Hrain Biotechnology) | - | - | detail > | |
| GCK-02 | GCK-02 | CAR-NK | Neoplasms Hemic and Lymphatic Diseases | CD33 inhibitors CLL-1 inhibitors Gene transference Natural killer cell replacements | Shanghai Jingshan Biotechnology Co., Ltd. | Shanghai Jingshan Biotechnology Co., Ltd. | Discovery | Discovery | - | - | - | - | - | - | - | - | GCK-02 | - | - | detail > | |
| CD33HSC/CD33 CAR-T(Tmunity Therapeutics) | CD33HSC/CD33 CAR-T(Tmunity Therapeutics) | Stem cell therapy | Neoplasms Hemic and Lymphatic Diseases | CD33 modulators | Tmunity Therapeutics, Inc. | Tmunity Therapeutics, Inc. | Preclinical | - | - | - | - | - | - | - | - | - | CD33HSC/CD33 CAR-T(Tmunity Therapeutics) | - | - | detail > |
Total 149 data
1
2
3
4
5
6
...
14
15
